Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with SyntArray, LLC

MINNEAPOLIS, March 13, 2018 (GLOBE NEWSWIRE)  Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, announced today that its wholly owned subsidiary, TumorGenesis Inc., has secured a license agreement with SyntArray LLC. This license agreement will advance the Company’s strategic plan to develop the next generation of patient derived (“PDx”) tumor models for precision cancer therapy and drug development by granting it access to SyntArray’s targeted peptide cell capture technology. TumorGenesis is developing a new approach to growing tumor The post Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with SyntArray, LLC appeared first on Public Wire.
http://bit.ly/2GtFWkg